Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 180-185

  Rydgren, Tobias ^a   Vaarala, Outi ^b   Sandler, Stellan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORPHOLOGY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; PRIORITY JOURNAL; RECURRENT DISEASE; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED NOD; RECURRENCE; SIMVASTATIN; STREPTOZOCIN;

EID: 34548858217     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.122655     Document Type: Article

References (23)

1. Bach JF (1995) Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. J Autoimmun 8:439-463.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, and Gotto AM (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279:1615-1622.
3. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, and Hirsch R (1992) Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41:385-391.
4. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524-1530.
5. Like AA and Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415-417.
6. Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, and Harlan JM (1999) Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 274:33334-33340.
7. Lozanoska-Ochser B, Barone F, Pitzalis C, and Peakman M (2006) Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic β-cell-specific CD8 T-cells. Diabetes 55:1004-1010.
8. Martin S, Hibino T, Faust A, Kleemann R, and Kolb H (1996) Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune insulitis of NOD mice and association with both Th1- and Th2-type infiltrates. J Autoimmun 9:637-643.
9. Niwa S, Totsuka T, and Hayashi S (1996) Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18:669-675.
10. Nomikos IN, Prowse SJ, Carotenuto P, and Lafferty KJ (1986) Combined treatment with nicotinamide and desferrioxamine prevents islets allograft destruction in NOD mice. Diabetes 35:1302-1304.
11. Paik SG, Fleischer N, and Shin SI (1980) Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc Natl Acad Sci U S A 77:6129-6133.
12. Palomer X, Calpe-Berdiel L, Verdaguer J, Carillo J, Pastor X, Mauricio D, and Blanco-Vaca F (2005) Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. Diabetologia 48:1671-1673.
13. Panerai AE, Nicoletti F, Sacedote P, Arvidsson L, Conget I, Gomis R, Bartorelli A, and Sandler S (2001) MFP14, a multifunctional emerging protein with immunomodulatory properties, prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetologia 44:839-847.
14. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, and Braunwald E (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844.
15. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, et al. (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80:1095-1100.
16. Sandberg JO, Eizirik DL, and Sandler S (1997) IL-1 receptor antagonist inhibits recurrence of disease after syngeneic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 108:314-317.
17. Sandler S and Andersson A (1985) Modulation of streptozotocin-induced insulitis and hyperglycaemia in the mouse. Acta Pathol Microbiol Immunol Scand [A] 93:93-98.
18. Sandler S, Andersson A, and Hellerstrom C (1987) Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 121:1424-1431.
19. Sandler S, Andersson AK, Barbu A, Hellerstrom C, Holstad M, Karlsson E, Sandberg JO, Strandell E, Saldeen J, Sternesjo J, et al. (2000) Novel experimental strategies to prevent the development of type 1 diabetes mellitus. Ups J Med Sci 105:17-34.
20. Takeuchi S, Kawashima S, Rikitake Y, Ueyama T, Inoue N, Hirata K, and Yokoyama M (2000) Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 269: 97-102.
21. Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482-486.
22. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, and Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692.
23. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, and Numano F (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 21:1165-1171.